MDRNA, Inc. Shareholders Approve Acquisition of Cequent Pharmaceuticals, Inc.
7/22/2010 10:12:32 AM
More...
|
Cequent Pharmaceuticals, Inc. Announces European Patent Office Intent to Grant and Korean Patent Office Notice of Decision to Award First Patents Covering tkRNAi Therapeutics
6/22/2010 11:44:29 AM
More...
|
Cequent Pharmaceuticals, Inc. Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate
4/15/2010 10:23:08 AM
More...
|
MDRNA, Inc. to Buy Privately Held Cequent Pharmaceuticals, Inc. for $46 Million
4/1/2010 6:29:58 AM
More...
|
FDA Grants Cequent Pharmaceuticals, Inc. IND
12/10/2009 11:25:26 AM
More...
|
Cequent Pharmaceuticals, Inc. Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology First Orally Delivered RNAi Investigational Drug to be Tested in Humans
11/12/2009 8:46:29 AM
More...
|
Cequent Pharmaceuticals, Inc. Closes Tranche of $10.8 Million Round
11/2/2009 8:04:11 AM
More...
|
Cequent Pharmaceuticals, Inc. to Provide Details at BIOCOM About Planned Launch of its Clinical Program
10/13/2009 8:43:10 AM
More...
|
Cequent Pharmaceuticals, Inc. Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
6/2/2009 11:42:33 AM
More...
|
Cequent Pharmaceuticals, Inc. tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
4/16/2009 11:51:10 AM
More...
|
|